Literature DB >> 29864904

Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142.

Guangling Yang1, Ruipeng Song1, Limin Wang1, Xuejian Wu2.   

Abstract

Long non-coding RNA P73 antisense RNA 1 T (lncRNA TP73-AS1) has been shown to involve in the progression of numerous tumors. Nevertheless, the expression as well as the functional mechanisms of TP73-AS1 in osteosarcoma (OS) are still largely unknown. This study aimed to explore the roles and underlying mechanism of TP73-AS1 in OS progression. In thye present study, TP73-AS1 expression was significantly increased in OS tissues and cell lines. High TP73-AS1 expression was associated with poor overall survival of OS patients. TP73-AS1 knockdown suppressed OS cells proliferation and invasion in vitro as well as tumor growth in vivo. Furthermore, we identified that miR-142 could act as a direct target for TP73-AS1 and miR-142 inhibition reversed the suppression of OS cells proliferation and invasion induced by TP73-AS1 knockdown. In addition, we showed that TP73-AS1 could function as a sponge of miR-142 to positively regulate Rac1 in OS cells. Thus, our data suggested that TP73-AS1 served as an oncogenic lncRNA in OS progression, and could be regarded as an efficient therapeutic target in the treatment of OS.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Osteosarcoma; Rac1; TP73-AS1; miR-142

Mesh:

Substances:

Year:  2018        PMID: 29864904     DOI: 10.1016/j.biopha.2018.04.146

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  11 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer.

Authors:  Jichuan Xu; Jian Xu; Xinyuan Liu; Jianxin Jiang
Journal:  Cell Death Discov       Date:  2022-06-14

3.  TP73-AS1 as a predictor of clinicopathological parameters and prognosis in human malignancies: a meta and bioinformatics analysis.

Authors:  Caizhi Chen; Jingjing Wang; Yeqian Feng; Ye Liang; Yan Huang; Wen Zou
Journal:  BMC Cancer       Date:  2022-05-25       Impact factor: 4.638

4.  Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis.

Authors:  Bin Wang; Xing Sun; Ke-Jian Huang; Li-Sheng Zhou; Zheng-Jun Qiu
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

5.  Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis.

Authors:  Yuan Zhong; Meng Zhao; Yang Yu; Quanpeng Li; Fei Wang; Peiyao Wu; Wen Zhang; Lin Miao
Journal:  Sci Rep       Date:  2020-06-03       Impact factor: 4.379

6.  The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206.

Authors:  Dan Fei; Guoqing Sui; Yang Lu; Long Tan; Zhao Dongxu; Kewei Zhang
Journal:  J Cell Mol Med       Date:  2018-12-19       Impact factor: 5.310

7.  The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.

Authors:  Wenchao Zhang; Xiaolei Ren; Lin Qi; Chenghao Zhang; Chao Tu; Zhihong Li
Journal:  BMC Cancer       Date:  2021-02-27       Impact factor: 4.430

8.  Role of long non-coding RNA TP73-AS1 in cancer.

Authors:  Caizhi Chen; Long Shu; Wen Zou
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

9.  LncRNA TP73-AS1 Activates TGF-β1 to Promote the Migration and Invasion of Colorectal Cancer Cell.

Authors:  Mingli Li; Yuanyuan Jin; Yuanzhi Li
Journal:  Cancer Manag Res       Date:  2019-12-16       Impact factor: 3.989

Review 10.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.